Abe Asami, Wakaki Kunihiko, Ishikawa Hajime, Ito Satoshi, Murasawa Akira
a Department of Rheumatology , Niigata Rheumatic Center , Niigata , Japan and.
b Department of Pathology , Niigata Prefectural Shibata Hospital , Niigata , Japan.
Mod Rheumatol. 2018 May;28(3):550-554. doi: 10.3109/14397595.2015.1115160. Epub 2015 Dec 23.
Methotrexate (MTX) is the first choice disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis (RA) and is referred to as an "anchor drug"; its use has been steadily increasing annually. However, MTX-related lymphoproliferative diseases (MTX-LPDs) have emerged as important complications in the patients with RA. There have been no reports of intra-articular MTX-LPDs of the patients with RA. Atypical cells were found in the patient's joint fluid by cytological examinations, and MTX-LPDs were suspected. The patient discontinued MTX and open synovectomy was performed. The histological findings and immunohistochemical staining of the specimens confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL) of MTX-LPDs. After the operation of the patient's left knee joint, pains and swollen joint disappeared with no relapse. The cytological examinations of the synovial fluid followed by knee operation were effective for early diagnosis of MTX-LPD. MTX discontinuation with no chemotherapy followed up with a knee operation improved the recovery of the MTX-LPD.
甲氨蝶呤(MTX)是类风湿关节炎(RA)的首选改善病情抗风湿药(DMARD),被称为“锚定药物”;其使用量每年都在稳步增加。然而,甲氨蝶呤相关淋巴增殖性疾病(MTX-LPDs)已成为类风湿关节炎患者的重要并发症。目前尚无类风湿关节炎患者关节内MTX-LPDs的报道。通过细胞学检查在患者关节液中发现非典型细胞,怀疑为MTX-LPDs。患者停用MTX并进行了开放性滑膜切除术。标本的组织学检查结果和免疫组化染色证实诊断为MTX-LPDs的弥漫性大B细胞淋巴瘤(DLBCL)。患者左膝关节手术后,疼痛和关节肿胀消失,未复发。膝关节手术前行滑膜液细胞学检查对MTX-LPDs的早期诊断有效。停用MTX且不进行化疗,随后进行膝关节手术,改善了MTX-LPDs的恢复情况。